Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery

Abstract

Successful outcome of immune checkpoint blockade in patients with solid cancers is in part associated with a high tumor mutational burden (TMB) and the recognition of private neoantigens by T-cells. The quality and quantity of target recognition is determined by the repertoire of ‘neoepitope’-specific T-cell receptors (TCRs) in tumor-infiltrating lymphocytes (TIL), or peripheral T-cells. Interferon gamma (IFN-γ), produced by T-cells and other immune cells, is essential for controlling proliferation of transformed cells, induction of apoptosis and enhancing human leukocyte antigen (HLA) expression, thereby increasing immunogenicity of cancer cells. TCR αβ-dependent therapies should account for tumor heterogeneity and availability of the TCR repertoire capable of reacting to neoepitopes and functional HLA pathways. Immunogenic epitopes in the tumor-stroma may also be targeted to achieve tumor-containment by changing the immune-contexture in the tumor microenvironment (TME). Non protein-coding regions of the tumor-cell genome may also contain many aberrantly expressed, non-mutated tumor-associated antigens (TAAs) capable of eliciting productive anti-tumor immune responses. Whole-exome sequencing (WES) and/or RNA sequencing (RNA-Seq) of cancer tissue, combined with several layers of bioinformatic analysis is commonly used to predict possible neoepitopes present in clinical samples. At the ImmunoSurgery Unit of the Champalimaud Centre for the Unknown (CCU), a pipeline combining several tools is used for predicting private mutations from WES and RNA-Seq data followed by the construction of synthetic peptides tailored for immunological response assessment reflecting the patient’s tumor mutations, guided by MHC typing. Subsequent immunoassays allow the detection of differential IFN-γ production patterns associated with (intra-tumoral) spatiotemporal differences in TIL or peripheral T-cells versus TIL. These bioinformatics tools, in addition to histopathological assessment, immunological readouts from functional bioassays and deep T-cell ‘adaptome’ analyses, are expected to advance discovery and development of next-generation personalized precision medicine strategies to improve clinical outcomes in cancer in the context of i) anti-tumor vaccination strategies, ii) gauging mutation-reactive T-cell responses in biological therapies and iii) expansion of tumor-reactive T-cells for the cellular treatment of patients with cancer.

mRNA vaccine in cancer therapy: Current advance and future outlook

“…Although SAMs have gained extensive attention and have been an inspiring alternative to mRNA‐based vaccines, clinical applications for cancer treatment are only limited to early assessment of viral replication particles 209 . With the discovery of neoantigens, personalized vaccines combined with checkpoint blockade modulators or cytokine cocktails are popularized to boost the host anti‐tumour immunity and facilitate the likelihood of tumour cell eradication 210,211 . Personalized neoantigen‐based cancer vaccines served as tumour‐specific therapies, compared to tumour‐associated antigens, neoantigen‐specific T cells are likely to survive during the progression of immune self‐tolerance, which augments robust T cell response and intensifies the breadth and diversity of the response.…”

Nanomaterials: small particles show huge possibilities for cancer immunotherapy

“…The vigorous development of sequencing technology has led to a deeper understanding of the process of tumor development and the discovery of many immune-related markers of tumors. TAAs (tumor-associated antigens) induce immune cells to recognize and trigger the body's immune response is a common means of tumor immunotherapy [ 41 , 42 ]. However, the cunning tumor cells also make this scheme ineffective by adjusting the expression of the corresponding proteins in the process.…”

Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort

“…TMB has been proved to be a useful biomarker for ICIs selection of some cancer types, such as NSCLCs, melanoma, and colorectal cancer; high TMB favors the infiltration of immune effector cells, and anti-tumor immune response [24]. However, cancers such those of the breast, kidney, and ovary display intermediate levels of mutational load [5].…”